Insulin analogues in type 1 diabetes mellitus: Getting better all the time

Nature Reviews Endocrinology

Volumn 13, Issue 7, 2017, Pages 385-399

  Mathieu, Chantal ^a   Gillard, Pieter ^a   Benhalima, Katrien ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

INSULIN ASPART; INSULIN ASPART PLUS INSULIN DEGLUDEC; INSULIN DEGLUDEC; INSULIN DERIVATIVE; INSULIN DETEMIR; INSULIN GLARGINE; INSULIN GLULISINE; INSULIN LISPRO; INSULIN PEGLISPRO; INSULIN ZINC SUSPENSION; ISOPHANE INSULIN; PIG INSULIN; ANTIDIABETIC AGENT; INSULIN; LONG ACTING INSULIN;

ANTIDIABETIC ACTIVITY; CLINICAL TRIAL (TOPIC); DIABETIC ANGIOPATHY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG FORMULATION; DRUG PENETRATION; DRUG RECEPTOR BINDING; DRUG RESEARCH; EVIDENCE BASED MEDICINE; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; INSULIN TREATMENT; NONHUMAN; OUTCOME ASSESSMENT; PHARMACODYNAMICS; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SIDE EFFECT; SYSTEMATIC REVIEW (TOPIC); TREATMENT DURATION; WEIGHT GAIN; ANALOGS AND DERIVATIVES; ANIMAL; CHEMISTRY; DIABETES MELLITUS, TYPE 1;

ANIMALS; DIABETES MELLITUS, TYPE 1; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN, LONG-ACTING;

EID: 85018278053     PISSN: 17595029     EISSN: 17595037     Source Type: Journal    
DOI: 10.1038/nrendo.2017.39     Document Type: Review

References (138)

1. Atkinson, M. A., Eisenbarth, G. S. & Michels, A. W. Type 1 diabetes. Lancet 383, 69-82 (2014).
2. Donner, T. Insulin - pharmacology, therapeutic regimens and principles of intensive insulin therapy. Endotext https://www.ncbi.nlm.nih.gov/books/NBK278938/ (2000).
3. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N. Engl. J. Med. 329, 977-986 (1993).
4. Nathan, D. M. & DCCT/EDIC Research Group. The diabetes control and complications trial/epidemiology of diabetes interventions and complications study at 30 years: overview. Diabetes Care 37, 9-16 (2014).
5. Home, P. D. The pharmacokinetics and pharmacodynamics of rapid-acting insulin analogues and their clinical consequences. Diabetes Obes. Metab. 14, 780-788 (2012).
6. de la Pena, A. et al. Pharmacokinetics and pharmacodynamics of high-dose human regular U-500 insulin versus human regular U-100 insulin in healthy obese subjects. Diabetes Care 34, 2496-2501 (2011).
7. Heise, T. et al. Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes. Diabetes 53, 1614-1620 (2004).
8. Heise, T. & Pieber, T. R. Towards peakless, reproducible and long-acting insulins. An assessment of the basal analogues based on isoglycaemic clamp studies. Diabetes Obes. Metab. 9, 648-659 (2007).
9. Lucidi, P. et al. Pharmacokinetics and pharmacodynamics of therapeutic doses of basal insulins NPH, glargine, and detemir after 1 week of daily administration at bedtime in type 2 diabetic subjects: a randomized cross-over study. Diabetes Care 34, 1312-1314 (2011).
10. Brange, J., Owens, D. R., Kang, S. & Volund, A. Monomeric insulins and their experimental and clinical implications. Diabetes Care 13, 923-954 (1990).
11. Heinemann, L. et al. Prandial glycaemia after a carbohydrate-rich meal in type I diabetic patients: using the rapid acting insulin analogue [Lys(B28), Pro(B29)] human insulin. Diabet. Med. 13, 625-629 (1996).
12. ter Braak, E. W. et al. Injection site effects on the pharmacokinetics and glucodynamics of insulin lispro and regular insulin. Diabetes Care 19, 1437-1440 (1996).
13. Tamas, G. et al. Glycaemic control in type 1 diabetic patients using optimised insulin aspart or human insulin in a randomised multinational study. Diabetes Res. Clin. Pract. 54, 105-114 (2001).
14. Valle, D., Santoro, D., Bates, P., Scarpa, L. & Italian Multicentre Lispro Study Group. Italian multicentre study of intensive therapy with insulin lispro in 1184 patients with type 1 diabetes. Diabetes Nutr. Metab. 14, 126-132 (2001).
15. Lindholm, A., McEwen, J. & Riis, A. P. Improved postprandial glycemic control with insulin aspart. A randomized double-blind cross-over trial in type 1 diabetes. Diabetes Care 22, 801-805 (1999).
16. Home, P. D., Barriocanal, L. & Lindholm, A. Comparative pharmacokinetics and pharmacodynamics of the novel rapid-acting insulin analogue, insulin aspart, in healthy volunteers. Eur. J. Clin. Pharmacol. 55, 199-203 (1999).
17. Plank, J. et al. A direct comparison of insulin aspart and insulin lispro in patients with type 1 diabetes. Diabetes Care 25, 2053-2057 (2002).
18. Homko, C., Deluzio, A., Jimenez, C., Kolaczynski, J. W. & Boden, G. Comparison of insulin aspart and lispro: pharmacokinetic and metabolic effects. Diabetes Care 26, 2027-2031 (2003).
19. Bartolo, P. D. et al. Better postprandial glucose stability during continuous subcutaneous infusion with insulin aspart compared with insulin lispro in patients with type 1 diabetes. Diabetes Technol. Ther. 10, 495-498 (2008).
20. Bode, B. et al. Comparison of insulin aspart with buffered regular insulin and insulin lispro in continuous subcutaneous insulin infusion: a randomized study in type 1 diabetes. Diabetes Care 25, 439-444 (2002).
21. Dreyer, M. et al. Efficacy and safety of insulin glulisine in patients with type 1 diabetes. Horm. Metab. Res. 37, 702-707 (2005).
22. Home, P. D., Lindholm, A., Riis, A. & European Insulin Aspart Study Group. Insulin aspart versus human insulin in the management of long-term blood glucose control in type 1 diabetes mellitus: a randomized controlled trial. Diabet. Med. 17, 762-770 (2000).
23. Raskin, P., Guthrie, R. A., Leiter, L., Riis, A. & Jovanovic, L. Use of insulin aspart, a fast-acting insulin analog, as the mealtime insulin in the management of patients with type 1 diabetes. Diabetes Care 23, 583-588 (2000).
24. Becker, R. H., Frick, A. D., Burger, F., Potgieter, J. H. & Scholtz, H. Insulin glulisine, a new rapid-acting insulin analogue, displays a rapid time-action profile in obese non-diabetic subjects. Exp. Clin. Endocrinol. Diabetes 113, 435-443 (2005).
25. Kerr, D., Wizemann, E., Senstius, J., Zacho, M. & Ampudia-Blasco, F. J. Stability and performance of rapid-acting insulin analogs used for continuous subcutaneous insulin infusion: a systematic review. J. Diabetes Sci. Technol. 7, 1595-1606 (2013).
26. Heise, T. et al. Insulin glulisine: a faster onset of action compared with insulin lispro. Diabetes Obes. Metab. 9, 746-753 (2007).
27. Arnolds, S. et al. Insulin glulisine has a faster onset of action compared with insulin aspart in healthy volunteers. Exp. Clin. Endocrinol. Diabetes 118, 662-664 (2010).
28. Luzio, S., Peter, R., Dunseath, G. J., Mustafa, L. & Owens, D. R. A comparison of preprandial insulin glulisine versus insulin lispro in people with type 2 diabetes over a 12-h period. Diabetes Res. Clin. Pract. 79, 269-275 (2008).
29. Bolli, G. B. et al. Comparative pharmacodynamic and pharmacokinetic characteristics of subcutaneous insulin glulisine and insulin aspart prior to a standard meal in obese subjects with type 2 diabetes. Diabetes Obes. Metab. 13, 251-257 (2011).
30. Garg, S. K., Rosenstock, J. & Ways, K. Optimized basal-bolus insulin regimens in type 1 diabetes: insulin glulisine versus regular human insulin in combination with basal insulin glargine. Endocr. Pract. 11, 11-17 (2005).
31. Fullerton, B. et al. Short-acting insulin analogues versus regular human insulin for adults with type 1 diabetes mellitus. Cochrane Database Syst. Rev. 6, CD012161 (2016).
32. Russell-Jones, D. et al. Fast-acting insulin aspart improves glycemic control in basal-bolus treatment for type 1 diabetes: Results of a 26-week multicenter, active-controlled, treat-to-target, randomized, parallel-group trial (Onset 1). Diabetes Care http://dx.doi.org/10.2337/dc16-1771 (2017).
33. DeVries, J. H. et al. A randomized trial of insulin aspart with intensified basal NPH insulin supplementation in people with type 1 diabetes. Diabet. Med. 20, 312-318 (2003).
34. Shafie, A. A., Ng, C. H., Tan, Y. P. & Chaiyakunapruk, N. Systematic review of the cost effectiveness of insulin analogues in type 1 and type 2 diabetes mellitus. Pharmacoeconomics 35, 141-162 (2017).
35. Pedersen-Bjergaard, U. et al. Short-term cost-effectiveness of insulin detemir and insulin aspart in people with type 1 diabetes who are prone to recurrent severe hypoglycemia. Curr. Med. Res. Opin. 32, 1719-1725 (2016).
36. American Diabetes Association. 8. Pharmacologic approaches to glycemic treatment. Diabetes Care 40, S64-S74 (2017).
37. Gonzalez Blanco, C., Chico Ballesteros, A., Gich Saladich, I. & Corcoy Pla, R. Glycemic control and pregnancy outcomes in women with type 1 diabetes mellitus using lispro versus regular insulin: a systematic review and meta-analysis. Diabetes Technol. Ther. 13, 907-911 (2011).
38. Mathiesen, E. R. et al. Maternal glycemic control and hypoglycemia in type 1 diabetic pregnancy: a randomized trial of insulin aspart versus human insulin in 322 pregnant women. Diabetes Care 30, 771-776 (2007).
39. Pozzilli, P. et al. Continuous subcutaneous insulin infusion in diabetes: patient populations, safety, efficacy, and pharmacoeconomics. Diabetes Metab. Res. Rev. 32, 21-39 (2016).
40. Kerr, D., Morton, J., Whately-Smith, C., Everett, J. & Begley, J. P. Laboratory-based non-clinical comparison of occlusion rates using three rapid-acting insulin analogs in continuous subcutaneous insulin infusion catheters using low flow rates. J. Diabetes Sci. Technol. 2, 450-455 (2008).
41. Brunner, G. A. et al. Pharmacokinetic and pharmacodynamic properties of long-acting insulin analogue NN304 in comparison to NPH insulin in humans. Exp. Clin. Endocrinol. Diabetes 108, 100-105 (2000).
42. Porcellati, F., Bolli, G. B. & Fanelli, C. G. Pharmacokinetics and pharmacodynamics of basal insulins. Diabetes Technol. Ther. 13 (Suppl. 1), S15-S24 (2011).
43. Rosenstock, J., Park, G., Zimmerman, J. & U.S. Insulin Glargine (HOE 901) Type 1 Diabetes Investigator Group. Basal insulin glargine (HOE 901) versus NPH insulin in patients with type 1 diabetes on multiple daily insulin regimens. Diabetes Care 23, 1137-1142 (2000).
44. Albright, E. S., Desmond, R. & Bell, D. S. Efficacy of conversion from bedtime NPH insulin injection to once- or twice-daily injections of insulin glargine in type 1 diabetic patients using basal/bolus therapy. Diabetes Care 27, 632-633 (2004).
45. Ratner, R. E. et al. Less hypoglycemia with insulin glargine in intensive insulin therapy for type 1 diabetes. U.S. study group of insulin glargine in type 1 diabetes. Diabetes Care 23, 639-643 (2000).
46. Dornhorst, A. et al. Safety and efficacy of insulin detemir in clinical practice: 14-week follow-up data from type 1 and type 2 diabetes patients in the PREDICTIVE European cohort. Int. J. Clin. Pract. 61, 523-528 (2007).
47. Hermansen, K., Dornhorst, A. & Sreenan, S. Observational, open-label study of type 1 and type 2 diabetes patients switching from human insulin to insulin analogue basal-bolus regimens: insights from the PREDICTIVE study. Curr. Med. Res. Opin. 25, 2601-2608 (2009).
48. [No authors listed.] Top 50 pharmaceutical products by global sales. PMLiVE http://www.pmlive.com/top-pharma-list/Top-50-pharmaceutical-products-by-global-sales (2017).
49. Lepore, M. et al. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes 49, 2142-2148 (2000).
50. Porcellati, F. et al. Pharmacokinetics and pharmacodynamics of the long-acting insulin analog glargine after 1 week of use compared with its first administration in subjects with type 1 diabetes. Diabetes Care 30, 1261-1263 (2007).
51. Hilgenfeld, R. et al. Controlling insulin bioavailability by crystal contact engineering. Diabetologia 35, A193 (1992).
52. Klein, O. et al. Albumin-bound basal insulin analogues (insulin detemir and NN344): comparable time-action profiles but less variability than insulin glargine in type 2 diabetes. Diabetes Obes. Metab. 9, 290-299 (2007).
53. Ashwell, S. G., Gebbie, J. & Home, P. D. Optimal timing of injection of once-daily insulin glargine in people with type 1 diabetes using insulin lispro at meal-times. Diabet. Med. 23, 46-52 (2006).
54. Havelund, S. et al. The mechanism of protraction of insulin detemir, a long-acting, acylated analog of human insulin. Pharm. Res. 21, 1498-1504 (2004).
55. Pieber, T. R. et al. Duration of action, pharmacodynamic profile and between-subject variability of insulin detemir in subjects with type 1 diabetes. Diabetes 51, A53 (2002).
56. Pieber, T. R. et al. Comparison of insulin detemir and insulin glargine in subjects with type 1 diabetes using intensive insulin therapy. Diabet. Med. 24, 635-642 (2007).
57. Heller, S., Koenen, C. & Bode, B. Comparison of insulin detemir and insulin glargine in a basal-bolus regimen, with insulin aspart as the mealtime insulin, in patients with type 1 diabetes: a 52-week, multinational, randomized, open-label, parallel-group, treat to target noninferiority trial. Clin. Ther. 31, 2086-2097 (2009).
58. Plank, J. et al. A double-blind, randomized, dose-response study investigating the pharmacodynamic and pharmacokinetic properties of the long-acting insulin analog detemir. Diabetes Care 28, 1107-1112 (2005).
59. Koehler, G. et al. Pharmacodynamics of the long-acting insulin analogues detemir and glargine following single-doses and under steady-state conditions in patients with type 1 diabetes. Diabetes Obes. Metab. 16, 57-62 (2014).
60. Danne, T. et al. Insulin detemir is characterized by a more reproducible pharmacokinetic profile than insulin glargine in children and adolescents with type 1 diabetes: results from a randomized, double-blind, controlled trial. Pediatr. Diabetes 9, 554-560 (2008).
61. De Leeuw, I. et al. Insulin detemir used in basal-bolus therapy in people with type 1 diabetes is associated with a lower risk of nocturnal hypoglycaemia and less weight gain over 12 months in comparison to NPH insulin. Diabetes Obes. Metab. 7, 73-82 (2005).
62. Tricco, A. C. et al. Safety, effectiveness, and cost effectiveness of long acting versus intermediate acting insulin for patients with type 1 diabetes: systematic review and network meta-analysis. BMJ 349, g5459 (2014).
63. Frier, B. M., Russell-Jones, D. & Heise, T. A comparison of insulin detemir and neutral protamine Hagedorn (isophane) insulin in the treatment of diabetes: a systematic review. Diabetes Obes. Metab. 15, 978-986 (2013).
64. Rosenstock, J. et al. A randomised, 52 week, treat to target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetologia 51, 408-416 (2008).
65. Hordern, S. V. & Russell-Jones, D. L. Insulin detemir, does a new century bring a better basal insulin? Int. J. Clin. Pract. 59, 730-739 (2005).
66. Herring, R. et al. Effect of subcutaneous insulin detemir on glucose flux, lipolysis and electroencephalography in type 1 diabetes. Diabetes Obes. Metab. 17, 1100-1103 (2015).
67. Pollex, E., Moretti, M. E., Koren, G. & Feig, D. S. Safety of insulin glargine use in pregnancy: a systematic review and meta-analysis. Ann. Pharmacother. 45, 9-16 (2011).
68. Blumer, I. et al. Diabetes and pregnancy: an endocrine society clinical practice guideline. J. Clin. Endocrinol. Metab. 98, 4227-4249 (2013).
69. Mathiesen, E. R. et al. Maternal efficacy and safety outcomes in a randomized, controlled trial comparing insulin detemir with NPH insulin in 310 pregnant women with type 1 diabetes. Diabetes Care 35, 2012-2017 (2012).
70. Tan, C. Y., Wilson, D. M. & Buckingham, B. Initiation of insulin glargine in children and adolescents with type 1 diabetes. Pediatr. Diabetes 5, 80-86 (2004).
71. Thalange, N., Bereket, A., Larsen, J., Hiort, L. C. & Peterkova, V. Treatment with insulin detemir or NPH insulin in children aged 2-5 yr with type 1 diabetes mellitus. Pediatr. Diabetes 12, 632-641 (2011).
72. National Institute for Health and Care Excellence. Type 1 diabetes in adults: diagnosis and management. NICE https://www.nice.org.uk/guidance/ng17 (2015).
73. Ashwell, S. G. et al. Improved glycaemic control with insulin glargine plus insulin lispro: a multicentre, randomized, cross-over trial in people with type 1 diabetes. Diabet. Med. 23, 285-292 (2006).
74. Pedersen-Bjergaard, U. et al. Effect of insulin analogues on risk of severe hypoglycaemia in patients with type 1 diabetes prone to recurrent severe hypoglycaemia (HypoAna trial): a prospective, randomised, open-label, blinded-endpoint crossover trial. Lancet Diabetes Endocrinol. 2, 553-561 (2014).
75. Taki, K. et al. Analysis of 24-hour glycemic excursions in patients with type 1 diabetes by using continuous glucose monitoring. Diabetes Technol. Ther. 12, 523-528 (2010).
76. Maia, F. F. & Araujo, L. R. Efficacy of continuous glucose monitoring system (CGMS) to detect postprandial hyperglycemia and unrecognized hypoglycemia in type 1 diabetic patients. Diabetes Res. Clin. Pract. 75, 30-34 (2007).
77. European Medicines Agency. Abasaglar (previously Abasria). EMA http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002835/human-med-001790.jsp&mid=WC0b01ac058001d124 (2014).
78. US Food and Drug Administration. FDA approves Basaglar, the first "follow-on" insulin glargine product to treat diabetes. FDA https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm477734.htm (2015).
79. Linnebjerg, H. et al. Comparison of the pharmacokinetics and pharmacodynamics of LY2963016 insulin glargine and EU- and US approved versions of lantus insulin glargine in healthy subjects: three randomized euglycemic clamp studies. Diabetes Care 38, 2226-2233 (2015).
80. Linnebjerg, H. et al. Pharmacokinetics of the long-acting basal insulin LY2605541 in subjects with varying degrees of renal function. Clin. Pharmacol. Drug Dev. 5, 216-224 (2016).
81. Ilag, L. L. et al. Evaluation of immunogenicity of LY2963016 insulin glargine compared with Lantus® insulin glargine in patients with type 1 or type 2 diabetes mellitus. Diabetes Obes. Metab. 18, 159-168 (2016).
82. Hadjiyianni, I. et al. Efficacy and safety of LY2963016 insulin glargine in patients with type 1 and type 2 diabetes previously treated with insulin glargine. Diabetes Obes. Metab. 18, 425-429 (2016).
83. Linnebjerg, H. et al. Duration of action of two insulin glargine products, LY2963016 insulin glargine and Lantus insulin glargine, in subjects with type 1 diabetes mellitus. Diabetes Obes. Metab. 19, 33-39 (2016).
84. Sindelka, G., Heinemann, L., Berger, M., Frenck, W. & Chantelau, E. Effect of insulin concentration, subcutaneous fat thickness and skin temperature on subcutaneous insulin absorption in healthy subjects. Diabetologia 37, 377-380 (1994).
85. Becker, R. H., Nowotny, I., Teichert, L., Bergmann, K. & Kapitza, C. Low within- and between-day variability in exposure to new insulin glargine 300 U/ml. Diabetes Obes. Metab. 17, 261-267 (2015).
86. -1. Diabetes Care 38, 637-643 (2015).
87. Bergenstal, R. M. et al. Comparison of insulin glargine 300 U/mL and 100 U/mL in adults with type 1 diabetes: continuous glucose monitoring profiles and variability using morning or evening injections. Diabetes Care 40, 554-560 (2017).
88. Matsuhisa, M. et al. Sustained glycaemic control and less nocturnal hypoglycaemia with insulin glargine 300U/mL compared with glargine 100U/mL in Japanese adults with type 1 diabetes (EDITION JP 1 randomised 12-month trial including 6-month extension). Diabetes Res. Clin. Pract. 122, 133-140 (2016).
89. Home, P. D. et al. New insulin glargine 300 Units/mL versus glargine 100 Units/mL in people with type 1 diabetes: a randomized, phase 3a, open-label clinical trial (EDITION 4). Diabetes Care 38, 2217-2225 (2015).
90. Heller, S., Mathieu, C., Kapur, R., Wolden, M. L. & Zinman, B. A meta-analysis of rate ratios for nocturnal confirmed hypoglycaemia with insulin degludec versus insulin glargine using different definitions for hypoglycaemia. Diabet. Med. 33, 478-487 (2016).
91. Mathieu, C. et al. Efficacy and safety of insulin degludec in a flexible dosing regimen versus insulin glargine in patients with type 1 diabetes (BEGIN: Flex T1): a 26-week randomized, treat-to-target trial with a 26 week extension. J. Clin. Endocrinol. Metab. 98, 1154-1162 (2013).
92. Ratner, R. E. et al. Hypoglycaemia risk with insulin degludec compared with insulin glargine in type 2 and type 1 diabetes: a pre-planned meta-analysis of phase 3 trials. Diabetes Obes. Metab. 15, 175-184 (2013).
93. Heise, T. et al. Comparison of the pharmacokinetic and pharmacodynamic profiles of insulin degludec and insulin glargine. Expert Opin. Drug Metab. Toxicol. 11, 1193-1201 (2015).
94. Heise, T. et al. A new-generation ultra-long-acting basal insulin with a bolus boost compared with insulin glargine in insulin-naive people with type 2 diabetes: a randomized, controlled trial. Diabetes Care 34, 669-674 (2011).
95. Heise, T., Nosek, L., Bottcher, S. G., Hastrup, H. & Haahr, H. Ultra-long-acting insulin degludec has a flat and stable glucose-lowering effect in type 2 diabetes. Diabetes Obes. Metab. 14, 944-950 (2012).
96. Heise, T. & Meneghini, L. F. Insulin stacking versus therapeutic accumulation: understanding the differences. Endocr. Pract. 20, 75-83 (2014).
97. Heller, S. et al. Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial. Lancet 379, 1489-1497 (2012).
98. Lane, W. S. et al. Switch1: reduced hypoglycaemia with insulin degludec (IDeg) vs. insulin glargine (IGlar), both U100, in patients with T1D at high risk of hypoglycaemia: a randomized, double-blind, crossover trial [abstract LB 87]. American Diabetes Association (2016).
99. Galasso, S. et al. Switching from twice-daily glargine or detemir to once-daily degludec improves glucose control in type 1 diabetes. An observational study. Nutr. Metab. Cardiovasc. Dis. 26, 1112-1119 (2016).
100. Korsatko, S. et al. A comparison of the steady-state pharmacokinetic and pharmacodynamic profiles of 100 and 200 U/mL formulations of ultra-long-acting insulin degludec. Clin. Drug Investig. 33, 515-521 (2013).
101. Jonassen, I. et al. Design of the novel protraction mechanism of insulin degludec, an ultra-long-acting basal insulin. Pharm. Res. 29, 2104-2114 (2012).
102. Haahr, H. & Heise, T. A review of the pharmacological properties of insulin degludec and their clinical relevance. Clin. Pharmacokinet. 53, 787-800 (2014).
103. Thalange, N. et al. Insulin degludec in combination with bolus insulin aspart is safe and effective in children and adolescents with type 1 diabetes. Pediatr. Diabetes 16, 164-176 (2015).
104. Evans, M., Chubb, B. & Gundgaard, J. Cost-effectiveness of insulin degludec versus insulin glargine in adults with type 1 and type 2 diabetes mellitus. Diabetes Ther. http://dx.doi.org/10.1007/s13300-017-0236-9 (2017).
105. Landstedt-Hallin, L., Gundgaard, J., Ericsson, A. & Ellfors-Zetterlund, S. Cost-effectiveness of switching to insulin degludec from other basal insulins: evidence from Swedish real-world data. Curr. Med. Res. Opin. http://dx.doi.org/10.1080/03007995.2016.1277194 (2017).
106. Henry, R. R. et al. Basal insulin peglispro demonstrates preferential hepatic versus peripheral action relative to insulin glargine in healthy subjects. Diabetes Care 37, 2609-2615 (2014).
107. Sinha, V. P. et al. Single-dose pharmacokinetics and glucodynamics of the novel, long-acting basal insulin LY2605541 in healthy subjects. J. Clin. Pharmacol. 54, 792-799 (2014).
108. Caparrotta, T. M. & Evans, M. PEGylated insulin lispro, (LY2605541) - a new basal insulin analogue. Diabetes Obes. Metab. 16, 388-395 (2014).
109. Buse, J. B. et al. Randomized clinical trial comparing basal insulin peglispro and insulin glargine in patients with type 2 diabetes previously treated with basal insulin: IMAGINE 5. Diabetes Care 39, 92-100 (2016).
110. Garg, S. et al. A randomized clinical trial comparing basal insulin peglispro and insulin glargine, in combination with prandial insulin lispro, in patients with type 1 diabetes: IMAGINE 1. Diabetes Obes. Metab. 18 (Suppl. 2), 25-33 (2016).
111. 1c reduction with basal insulin peglispro (BIL) versus insulin glargine (GL) in an open-label, randomised study in type 1 diabetic patients: IMAGINE 1 [abstract 3]. Diabetologia 58 (Suppl. 1), S2 (2015).
112. Bergenstal, R. M. et al. Randomized, double-blind clinical trial comparing basal insulin peglispro and insulin glargine, in combination with prandial insulin lispro, in patients with type 1 diabetes: IMAGINE 3. Diabetes Obes. Metab. 18, 1081-1088 (2016).
113. Cusi, K. et al. Different effects of basal insulin peglispro and insulin glargine on liver enzymes and liver fat content in patients with type 1 and type 2 diabetes. Diabetes Obes. Metab. 18 (Suppl. 2), 50-58 (2016).
114. Munoz-Garach, A., Molina-Vega, M. & Tinahones, F. J. How can a good idea fail? Basal insulin peglispro [LY2605541] for the treatment of type 2 diabetes. Diabetes Ther. 8, 9-22 (2017).
115. Atkin, S., Javed, Z. & Fulcher, G. Insulin degludec and insulin aspart: novel insulins for the management of diabetes mellitus. Ther. Adv. Chronic Dis. 6, 375-388 (2015).
116. Heise, T. et al. Distinct prandial and basal glucose-lowering effects of insulin degludec/insulin aspart (IDegAsp) at steady state in subjects with type 1 diabetes mellitus. Diabetes Ther. 5, 255-265 (2014).
117. Hirsch, I. B., Franek, E., Mersebach, H., Bardtrum, L. & Hermansen, K. Safety and efficacy of insulin degludec/insulin aspart with bolus mealtime insulin aspart compared with standard basal-bolus treatment in people with type 1 diabetes: 1-year results from a randomized clinical trial (BOOST(R) T1). Diabet. Med. 34, 167-173 (2017).
118. Heise, T. et al. Faster-acting insulin aspart: earlier onset of appearance and greater early pharmacokinetic and pharmacodynamic effects than insulin aspart. Diabetes Obes. Metab. 17, 682-688 (2015).
119. de la Pena, A. et al. Bioequivalence and comparative pharmacodynamics of insulin lispro 200 U/mL relative to insulin lispro (Humalog®) 100 U/mL. Clin. Pharmacol. Drug Dev. 5, 69-75 (2016).
120. Muchmore, D. B. & Vaughn, D. E. Review of the mechanism of action and clinical efficacy of recombinant human hyaluronidase coadministration with current prandial insulin formulations. J. Diabetes Sci. Technol. 4, 419-428 (2010).
121. Muchmore, D. B. & Vaughn, D. E. Accelerating and improving the consistency of rapid-acting analog insulin absorption and action for both subcutaneous injection and continuous subcutaneous infusion using recombinant human hyaluronidase. J. Diabetes Sci. Technol. 6, 764-772 (2012).
122. Krasner, A. et al. A review of a family of ultra-rapid-acting insulins: formulation development. J. Diabetes Sci. Technol. 6, 786-796 (2012).
123. Pandyarajan, V. & Weiss, M. A. Design of non-standard insulin analogs for the treatment of diabetes mellitus. Curr. Diab. Rep. 12, 697-704 (2012).
124. Heise, T., Pieber, R. R., Danne, T., Erlichsen, L. & Haahr, H. Faster onset and greater early exposure and glucose-lowering effect with faster-acting insulin aspart versus insulin aspart: a pooled analysis in subjects with type 1 diabetes [abstract 929 P]. American Diabetes Association (2016).
125. Heise, T. et al. A comparison of pharmacokinetic and pharmacodynamic properties between faster-acting insulin aspart and insulin aspart in elderly subjects with type 1 diabetes mellitus. Drugs Aging 34, 29-38 (2017).
126. Fath, M. et al. Faster-acting insulin aspart provides faster onset and greater early exposure versus insulin aspart in children and adolescents with type 1 diabetes mellitus. Pediatr. Diabetes http://dx.doi.org/10.1111/pedi.12506 (2017).
127. Heise, T., Zijlstra, E., Nosek, L., Rikte, T. & Haahr, H. Pharmacological properties of faster-acting insulin aspart versus insulin aspart in patients with type 1 diabetes using continuous subcutaneous insulin infusion: a randomised, double-blind, crossover trial. Diabetes Obes. Metab. 19, 208-215 (2017).
128. Bode, B. W., Johnson, J. A., Hyveled, L., Tamer, S. C. & Demissie, M. Improved postprandial glycemic control with faster-acting insulin aspart in patients with type 1 diabetes using continuous subcutaneous insulin infusion. Diabetes Technol. Ther. 19, 25-33 (2017).
129. European Medicines Agency. Fiasp. EMA http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/004046/human-med-002063.jsp&mid=WC0b01ac058001d124 (2017).
130. Cengiz, E., Bode, B., Van Name, M. & Tamborlane, W. V. Moving toward the ideal insulin for insulin pumps. Expert Rev. Med. Devices 13, 57-69 (2016).
131. Zaykov, A. N., Mayer, J. P. & DiMarchi, R. D. Pursuit of a perfect insulin. Nat. Rev. Drug Discov. 15, 425-439 (2016).
132. Wang, Y., Shao, J., Zaro, J. L. & Shen, W. C. Proinsulin-transferrin fusion protein as a novel long-acting insulin analog for the inhibition of hepatic glucose production. Diabetes 63, 1779-1788 (2014).
133. Phillips, N. B., Whittaker, J., Ismail-Beigi, F. & Weiss, M. A. Insulin fibrillation and protein design: topological resistance of single-chain analogs to thermal degradation with application to a pump reservoir. J. Diabetes Sci. Technol. 6, 277-288 (2012).
134. Chou, D. H. et al. Glucose-responsive insulin activity by covalent modification with aliphatic phenylboronic acid conjugates. Proc. Natl Acad. Sci. USA 112, 2401-2406 (2015).
135. Baeshen, N. A. et al. Cell factories for insulin production. Microb. Cell Fact. 13, 141 (2014).
136. Santos Cavaiola, T. & Edelman, S. Inhaled insulin: a breath of fresh air? A review of inhaled insulin. Clin. Ther. 36, 1275-1289 (2014).
137. Heinemann, L. Insulin pens and new ways of insulin delivery. Diabetes Technol. Ther. 16 (Suppl. 1), S44-S55 (2014).
138. Fonte, P., Araujo, F., Reis, S. & Sarmento, B. Oral insulin delivery: how far are we? J. Diabetes Sci. Technol. 7, 520-531 (2013).